# First Line Therapy for High Risk Acute GVHD

> **NCT04061876** · PHASE2 · COMPLETED · sponsor: **Chinese PLA General Hospital** · enrollment: 198 (actual)

## Conditions studied

- aGVHD
- Stem Cell Transplant Complications

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Corticosteroid

## Key facts

- **NCT ID:** NCT04061876
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-25
- **Primary completion:** 2022-08-01
- **Final completion:** 2023-06-30
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2023-11-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04061876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04061876, "First Line Therapy for High Risk Acute GVHD". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04061876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*